The regulation of MDM2 oncogene and its impact on human cancers

被引:132
|
作者
Zhao, Yuhan [1 ]
Yu, Haiyang [1 ]
Hu, Wenwei [1 ,2 ]
机构
[1] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA
[2] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pediat, Dept Pharmacol, New Brunswick, NJ 08903 USA
基金
美国国家卫生研究院;
关键词
MDM2; E3 ubiquitin ligase; gene regulation; p53; TUMOR-SUPPRESSOR PATHWAY; P53-MDM2 FEEDBACK LOOP; UBIQUITIN LIGASE ACTIVITY; RIBOSOMAL-PROTEIN L26; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; ACTIVATES P53; MUTANT P53; P53-DEPENDENT MANNER; ONCOPROTEIN MDM2;
D O I
10.1093/abbs/gmt147
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor suppressor p53 plays a central role in preventing tumor formation. The levels and activity of p53 is under tight regulation to ensure its proper function. Murine double minute 2 (MDM2), a p53 target gene, is an E3 ubiquitin ligase. MDM2 is a key negative regulator of p53 protein, and forms an auto-regulatory feedback loop with p53. MDM2 is an oncogene with both p53-dependent and p53-independent oncogenic activities, and often has increased expression levels in a variety of human cancers. MDM2 is highly regulated; the levels and function of MDM2 are regulated at the transcriptional, translational and post-translational levels. This review provides an overview of the regulation of MDM2. Dysregulation of MDM2 impacts significantly upon the p53 functions, and in turn the tumorigenesis. Considering the key role that MDM2 plays in human cancers, a better understanding of the regulation of MDM2 will help us to develop novel and more effective cancer therapeutic strategies to target MDM2 and activate p53 in cells.
引用
收藏
页码:180 / 189
页数:10
相关论文
共 50 条
  • [31] THE PROTO-ONCOGENE, MDM2, IS REQUIRED FOR MAINTENANCE OF THE CAP MESENCHYME
    Hilliard, S. A.
    El-Dahr, S. S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (01) : 424 - 424
  • [32] Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers
    Tran, Hung N.
    Singh, Hardeep P.
    Guo, Wenxuan
    Cambier, Linda
    Riggan, Luke
    Shackleford, Gregory M.
    Thornton, Matthew E.
    Grubbs, Brendan H.
    Erdreich-Epstein, Anat
    Qi, Dong-Lai
    Cobrinik, David
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [33] The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation
    Tatiana Dilla
    Jesús Romero
    Pilar Sanstisteban
    Juan A Velasco
    Oncogene, 2002, 21 : 2376 - 2386
  • [34] ENHANCED TRANSLATION - A NOVEL MECHANISM OF MDM2 ONCOGENE OVEREXPRESSION IDENTIFIED IN HUMAN TUMOR-CELLS
    LANDERS, JE
    HAINES, DS
    STRAUSS, JF
    GEORGE, DL
    ONCOGENE, 1994, 9 (09) : 2745 - 2750
  • [35] Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress
    Singh, Ravi K.
    Tapia-Santos, Aixa
    Bebee, Thomas W.
    Chandler, Dawn S.
    EXPERIMENTAL CELL RESEARCH, 2009, 315 (19) : 3419 - 3432
  • [36] The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation
    Dilla, T
    Romero, J
    Sanstisteban, P
    Velasco, JA
    ONCOGENE, 2002, 21 (15) : 2376 - 2386
  • [37] Model predictions of MDM2 mediated cell regulation
    Obeyesekere, MN
    Tecarro, E
    Lozano, G
    CELL CYCLE, 2004, 3 (05) : 655 - 661
  • [38] LACK OF MDM2 AMPLIFICATION IN HUMAN LEUKEMIA
    RIDGE, SA
    DYER, M
    GREAVES, MF
    WIEDEMANN, LM
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (02) : 407 - 409
  • [39] Regulation of MDM2 Stability After DNA Damage
    Li, Jiaqi
    Kurokawa, Manabu
    JOURNAL OF CELLULAR PHYSIOLOGY, 2015, 230 (10) : 2318 - 2327
  • [40] Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma
    Endo, K
    Ueda, T
    Ohta, T
    Terada, T
    LIVER, 2000, 20 (03): : 209 - 215